Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

Who May Qualify: - 25 years or older. - Huntington's Disease confirmed through genetic testing, with a specific change in exon 1 of the HTT gene (CAG repeat of 40 or more). - Total Functional Capacity (TFC) score of 10 or more). - Total Motor Score (TMS) of 6 or more). - Independence Score (IS) of 70 or more). - Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug. - Men must agree to use birth control during the study and for 90 days after the last dose. - Agree to sign a consent form and follow the study's rules and schedule. Who Should NOT Join This Trial: - Other Serious health problems or brain/spinal issues that could interfere with the study or make procedures unsafe. - Conditions that interfere with protocol-specified assessments, like an implanted medical device or difficulty getting an MRI. - Cancer, except for some types of skin cancer, or a history of cancer in the last five years. - Severe allergies or have reacted badly to similar drugs in the past. - Taking medications or treatments that might interfere with the study. - Participated in another study or taken experimental drugs in the last two months (or longer for some drugs). - Any kind of gene therapy. - History of suicidal thoughts, severe depression, or have attempted suicide in the past year. - Liver function tests show significant abnormalities. - Positive for hepatitis B, hepatitis C, or HIV. - Pregnancy, breastfeeding, or planning to become pregnant during the study. Always talk to your doctor about whether this trial is right for you.